Comparing GeneDx (NASDAQ:WGS) & Kindly MD (NASDAQ:KDLY)

Kindly MD (NASDAQ:KDLY) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Kindly MD and GeneDx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kindly MD	0	0	0	0	N/A
GeneDx	0	3	3	0	2.50

GeneDx has a consensus price target of $59.33, indicating a potential downside of 23.68%. Given GeneDx’s higher possible upside, analysts clearly believe GeneDx is more favorable than Kindly MD.

Earnings and Valuation

This table compares Kindly MD and GeneDx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kindly MD	N/A	N/A	N/A	N/A	N/A
GeneDx	$202.57 million	10.34	-$175.77 million	($3.11)	-25.00

Kindly MD has higher earnings, but lower revenue than GeneDx.

Institutional and Insider Ownership

61.7% of GeneDx shares are owned by institutional investors. 50.5% of Kindly MD shares are owned by insiders. Comparatively, 27.3% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Kindly MD and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kindly MD	N/A	N/A	N/A
GeneDx	-31.25%	-13.35%	-6.91%

About Kindly MD

KindlyMD Inc. is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, including the recommendation of medical cannabis in patient treatment plans in compliance with a legalized state medical cannabis regulatory scheme. KindlyMD Inc. is based in SALT LAKE CITY, UT.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.